Willow Biosciences Inc
TSX:WLLW
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (115.2), the stock would be worth CA$1.17 (586% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 16.8 | CA$0.17 |
0%
|
| 3-Year Average | 115.2 | CA$1.17 |
+586%
|
| 5-Year Average | 314.7 | CA$3.19 |
+1 774%
|
| Industry Average | 18.2 | CA$0.18 |
+9%
|
| Country Average | 2.9 | CA$0.03 |
-83%
|
Forward P/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Willow Biosciences Inc
TSX:WLLW
|
107m CAD | 16.8 | -25.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 6.1 | 89.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 5.1 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 5.5 | 19.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 9 | 27.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 5.2 | 16.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 11.6 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 2.7 | 29.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.4 |
| Median | 2.9 |
| 70th Percentile | 4.9 |
| Max | 15 623 917.6 |
Other Multiples
Willow Biosciences Inc
Glance View
Willow Biosciences, Inc. is a biotechnology company. The company is headquartered in Calgary, Alberta and currently employs 49 full-time employees. The company went IPO on 2017-09-14. The firm's products include tetrahydrocannabinol (THC), cannabidiol (CBD), cannabidivarin (CBDV), cannabigerovarin (CBGV), tetrahydrocannabivarin (THCV) and cannabinol (CBN). The firm has two laboratories for research and development in Mountain View, California and Burnaby, British Columbia. In addition, the Company has an analytical testing lab in Burnaby where it provides third-party analytical testing and product development services to the cannabis industry through its subsidiary Willow Analytics Inc. The company also offers testing for all forms of cannabis products, including flower, concentrates and extracted ingredients.
